Bioanalysis Zone

Bioanalytical workflow for novel scaffold protein–drug conjugates: quantitation of total Centyrin protein, conjugated Centyrin and free payload for Centyrin–drug conjugate in plasma and tissue samples using liquid chromatography–tandem mass spectrometry


Antibody–drug conjugates (ADCs) hold great promise as therapeutic agents for cancer due to their capability to deliver potent cytotoxic agents to targeted cells, thereby reducing nontargeted exposure, increasing drug concentrations at the disease site and broadening the therapeutic window [1–5]. In recent years, ‘alternative scaffold’ proteins have also emerged as potential therapeutic agents for cancer [6–9]. Designed or natural proteins with simple, stable structures and highly specific affinity for biological targets have been explored to generate

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment